Abstract
A metronomic, low-dose schedule of decitabine and venetoclax was safe and effective in myeloid malignancies with few dose reductions or interruptions in an older diverse population. Median overall survival for patients with acute myeloid leukemia and a TP53-mutation was 16.1 and 11.3 months, respectively. This trial was registered at www.clinicaltrials.gov as #NCT05184842.
© 2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols* / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols* / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
-
Azacitidine / administration & dosage
-
Azacitidine / adverse effects
-
Azacitidine / analogs & derivatives
-
Azacitidine / therapeutic use
-
Bridged Bicyclo Compounds, Heterocyclic* / administration & dosage
-
Bridged Bicyclo Compounds, Heterocyclic* / adverse effects
-
Bridged Bicyclo Compounds, Heterocyclic* / therapeutic use
-
Cohort Studies
-
Decitabine* / administration & dosage
-
Decitabine* / adverse effects
-
Decitabine* / therapeutic use
-
Drug Administration Schedule
-
Female
-
Humans
-
Leukemia, Myeloid, Acute* / drug therapy
-
Leukemia, Myeloid, Acute* / mortality
-
Male
-
Middle Aged
-
Mutation
-
Sulfonamides* / administration & dosage
-
Sulfonamides* / adverse effects
-
Sulfonamides* / therapeutic use
-
Treatment Outcome
Substances
-
Azacitidine
-
Bridged Bicyclo Compounds, Heterocyclic
-
Decitabine
-
Sulfonamides
-
venetoclax
Associated data
-
ClinicalTrials.gov/NCT05184842